GlassScriptPhysician profile
Randal West
NPI 1861592339
$7,613.96
in general payments reported to CMS, 2019-2025
33 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,226 · 2020: $160 · 2021: $713 · 2022: $700 · 2023: $1,294 · 2024: $1,319 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,695 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,695.23 |
| Education | $119.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,968.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,006.62 | 2019-2025 | Lynparza |
| Eisai INC. | $743.21 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $712.00 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astellas Pharma US INC | $543.75 | 2021-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $503.33 | 2021-2025 | Jemperli, Zejula |
| Seagen INC. | $322.62 | 2021-2023 | Tivdak |
| Myriad Genetic Laboratories, INC. | $289.77 | 2021-2024 | Myrisk, Precisetumor, Mychoice Cdx |
| Abbvie INC. | $252.07 | 2021-2025 | Ubrelvy |
| Pfizer INC. | $205.34 | 2022-2025 | |
| Immunogen, INC. | $171.43 | 2023-2024 | Elahere, Elahere |
| Foundation Medicine, INC. | $100.40 | 2019 | |
| Amneal Pharmaceuticals LLC | $81.21 | 2025 | Alymsys |
| Conmed Corporation | $66.67 | 2019 | |
| Myovant Sciences INC. | $65.21 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Asd Specialty Healthcare, LLC | $61.76 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $60.82 | 2021 | |
| Coherus Oncology, INC. | $56.65 | 2021 | |
| Tempus Ai, INC | $46.10 | 2024 | Xt Cdx |
| Amgen INC. | $42.93 | 2020 | |
| Asensus Surgical, INC. | $34.30 | 2020 | |
| Smith+Nephew, INC. | $29.74 | 2022 | |
| Ethicon US, LLC | $28.86 | 2022 | |
| Tersera Therapeutics LLC | $28.34 | 2025 | Quzyttir |
| Daiichi Sankyo INC. | $25.75 | 2025 | Enhertu |
| Biohaven Pharmaceutical Holding Company LTD. | $24.83 | 2022 | |
| Spectrum Pharmaceuticals INC. | $23.20 | 2025 | Rolvedon |
| Accord Healthcare, INC. | $23.11 | 2025 | |
| Sumitomo Pharma America, INC. | $22.46 | 2025 | Myfembree |
| Rochester Medical Corporation | $21.24 | 2021 | |
| Collegium Pharmaceutical, INC. | $19.87 | 2025 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.02 | 2023 | Relistor |
| Clovis Oncology, INC. | $14.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randal West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.